Acuvue Oaysis Contact Lens Wearers Being Refit Into P7 Contact Lenses

NCT ID: NCT06955403

Last Updated: 2025-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-15

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Determine the likelihood of successfully refitting a satisfied AOA CL wearers into P7A CLs

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRECISION7m for Astigmatism is a 1-week, silicone hydrogel (serafilcon A), daily wear, contact lens (CL) with extended wear approval made of a novel material that incorporates the Activ-Flo System. The Activ-Flo System has a moisturizing agent within the CL matrix, which allows for continual release of the moisturizing agents while also providing up to 16 hours of comfortable wear and precise vision for the life of the CL. While initial P7A data are promising, the literature currently lacks a targeted study aimed at determining how patients perform in P7A after transitioning out of other commonly prescribed silicone hydrogel CLs. This transition could be particularly important for patients who have astigmatism given that they tend to struggle with CLs more than spherical CL wearers.1 Thus, the purpose of this study is to determine the success rate of refitting current, satisfied ACUVUE OASYS for Astigmatism CL wearers into P7A. Understanding how a P7A CL wearer reacts to transitioning into P7A from AOA will provide valuable information to partitioners for patient educational purposes, and it will provide credence for refitting successful AOA patients into the newer P7A technology, which could help grow the P7A CL market by not limiting P7A refits to problem-solving events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contact Lens Comfort

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This will be a prospective study to understand if satisfied AOA CL wearers can be successfully refit into P7A CLs. The Primary Endpoint will be analyzed as the proportion of participants who have CLDEQ-8 scores \<12 at the end of the study; thus, no comparison will occur with the Primary Endpoint and no formal sample size calculation can be performed
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRECISION7

Determine the likelihood of successfully refitting a satisfied Acuvue Oaysis Contact Lens wearers into P7A CLs.

Group Type EXPERIMENTAL

Precision 7 contact lenses

Intervention Type DEVICE

Acuvue Oaysis contact lens wearers have will be refit into precision 7 contact lenses.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Precision 7 contact lenses

Acuvue Oaysis contact lens wearers have will be refit into precision 7 contact lenses.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants will be required to have worn AOA CLs for at least 3 months in the past year and currently wearing these CLs.
* All participants will be required to have a CLDEQ-8 score \<12 while wearing their habitual CLs (AOA CLs) and to indicate that they are satisfied with AOA CLs (Yes/No).
* Participants will be required to be able to wear P7A CLs (astigmatism ≥0.75D OD/OS).
* Astigmatism ranging from 0.75 D to 2.50 D in each eye
* Participants will be required to wear the study CLs for ≥13 hours with no overnight wear
* Participants will be willing to wear the CL every day of the week, except during the washout period
* Participants will be required to provide a glasses prescription that is less than 3 years old
* \-

Exclusion Criteria

* \- Have presbyopia and/or need a reading add as determined during their initial manifest refraction
* Have worn P7A in the past
* Are past rigid CL wearers
* Have a history of being diagnosed with dry eye or ocular allergies
* Have known systemic health conditions that are thought to alter tear film physiology
* Have a history of viral eye disease
* Have a history of ocular surgery
* Have a history of severe ocular trauma
* Have a history of corneal dystrophies or degenerations
* Have active ocular infection or inflammation
* Are currently using isotretinoin-derivatives or ocular medications
* Are pregnant or breast feeding
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eminent Ophthalmic Services

UNKNOWN

Sponsor Role collaborator

Southern College of Optometry

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chris Lievens

Role: PRINCIPAL_INVESTIGATOR

The Southern College of Optometry

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Southern College of Optometry

Memphis, Tennessee, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chris Lievens, OD

Role: CONTACT

9014815699

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chris Lievens, OD

Role: primary

9014815699

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P7

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.